Amarin wanted an import ban on certain fish oil supplements.
In a win for consumer access to natural products, the Supreme Court has denied Amarin’s final petition for appeal in the company’s effort to corner the market on fish oil.
In 2017, Amarin asked the US International Trade Commission (ITC) to ban the importation of omega-3 dietary supplements composed mainly of EPA, known for its anti-inflammatory properties. The ITC sensibly decided not to pursue the issue, and Amarin appealed all the way to the Supreme Court.
We’re happy the issue has been resolved, as it would have been extraordinary if Amarin was able to win a monopoly on fish oil. Although Amarin has received FDA-approval for its Vascepa fish oil drug, fish oil was marketed years before those clinical trials began, meaning the supplement can stay on the market.
